{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T18:40:17Z","timestamp":1736188817638,"version":"3.32.0"},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>A single dose of intraperitoneal (IP) meropenem is recommended for peritoneal-dialysis (PD)-related peritonitis stemming from extended-spectrum \u03b2-lactamase-producing organisms. However, data on IP meropenem is limited.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This prospective, descriptive study was conducted to examine plasma and dialysate meropenem levels during continuous IP meropenem administration in five patients with PD-related peritonitis. All patients received an IP meropenem loading dose of 500 mg, followed by IP meropenem at 125 mg\/L, with four exchanges daily. The plasma and dialysate meropenem concentrations were measured at specified intervals for a 24-hour period utilizing a high-performance, liquid chromatography method.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Five patients with PD related peritonitis were studied. The mean-maximum dialysate and plasma meropenem levels were 158.1 mg\/L (standard deviation [SD] \u00b1 62.9) and 29.4 mg\/L (SD \u00b1 15.9), respectively. The mean dialysate meropenem level was at its minimum of 32.6 mg\/L (SD \u00b1 19.1) at 24 hours. Throughout the period, the dialysate meropenem levels exceeded the minimal inhibitory concentration of the pathogenic resistance organism (&gt; 8 mg\/L). Four patients responded to the treatment, whereas one developed treatment failure from fungal peritonitis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>An IP meropenem loading of 500 mg, followed by 125 mg\/L every 6 hours, provided an adequate dialysate meropenem concentration and is an effective treatment for PD related peritonitis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Trial registration<\/jats:title>\n<jats:p>Thai Clinical Trials Registry (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.thaiclinicaltrials.org\/show\/TCTR20191121002\" xlink:type=\"simple\">TCTR20191121002<\/jats:ext-link>) with date of first registration at 21\/11\/2019 (retrospectively registered).<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0312160","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T18:24:46Z","timestamp":1736187886000},"page":"e0312160","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dialysate and plasma meropenem concentrations in continuous intraperitoneal regimen during peritoneal-dialysis-related peritonitis"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5860-3395","authenticated-orcid":true,"given":"Thatsaphan","family":"Srithongkul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukit","family":"Raksasuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bulaporn","family":"Techajongnumchai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suchai","family":"Sritippayawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8860-640X","authenticated-orcid":true,"given":"Pornpan","family":"Koomanachai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"issue":"5","key":"pone.0312160.ref001","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3747\/pdi.2016.00078","article-title":"ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment","volume":"36","author":"PK-T Li","year":"2016","journal-title":"Perit Dial Int"},{"issue":"1","key":"pone.0312160.ref002","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12882-017-0588-4","article-title":"The impact of peritoneal dialysis-related peritonitis on mortality in peritoneal dialysis patients","volume":"18","author":"H Ye","year":"2017","journal-title":"BMC Nephrol"},{"issue":"4","key":"pone.0312160.ref003","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/ki.2010.149","article-title":"Predictors, treatment, and outcomes of non-Pseudomonas Gram-negative peritonitis","volume":"78","author":"EM Jarvis","year":"2010","journal-title":"Kidney Int"},{"issue":"7","key":"pone.0312160.ref004","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/sj.ki.5000037","article-title":"Enterobacteriaceae peritonitis complicating peritoneal dialysis: a review of 210 consecutive cases","volume":"69","author":"CC Szeto","year":"2006","journal-title":"Kidney Int"},{"issue":"4","key":"pone.0312160.ref005","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1128\/CMR.14.4.933-951.2001","article-title":"Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat","volume":"14","author":"PA Bradford","year":"2001","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl 2","key":"pone.0312160.ref006","doi-asserted-by":"crossref","first-page":"S272","DOI":"10.1177\/089686080702702s47","article-title":"Evolution of antibiotic resistance mechanisms and their relevance to dialysis-related infections","volume":"27","author":"SS Wong","year":"2007","journal-title":"Perit Dial Int"},{"issue":"2","key":"pone.0312160.ref007","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/089686080602600213","article-title":"Risk factors and outcomes of extended-spectrum beta-lactamase-producing E. coli peritonitis in CAPD patients","volume":"26","author":"T Yip","year":"2006","journal-title":"Perit Dial Int"},{"issue":"3","key":"pone.0312160.ref008","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3747\/pdi.2013.00012","article-title":"Escherichia coli Peritonitis in peritoneal dialysis: the prevalence, antibiotic resistance and clinical outcomes in a South China dialysis center","volume":"34","author":"X Feng","year":"2014","journal-title":"Perit Dial Int"},{"issue":"6","key":"pone.0312160.ref009","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3747\/pdi.2012.00155","article-title":"Intraperitoneal compared with intravenous meropenem for peritoneal dialysis-related peritonitis","volume":"33","author":"PJ Vlaar","year":"2013","journal-title":"Perit Dial Int"},{"issue":"5","key":"pone.0312160.ref010","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1128\/AAC.02664-15","article-title":"An Open, Randomized, Single-Center, Crossover Pharmacokinetic Study of Meropenem after Intraperitoneal and Intravenous Administration in Patients Receiving Automated Peritoneal Dialysis","volume":"60","author":"M Wiesholzer","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"pone.0312160.ref011","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1093\/ndt\/16.11.2240","article-title":"Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis","volume":"16","author":"SH Chung","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"pone.0312160.ref012","first-page":"CD005284","article-title":"Treatment for peritoneal dialysis-associated peritonitis","volume":"4","author":"AE Ballinger","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"pone.0312160.ref013","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3747\/pdi.2015.00008","article-title":"Pharmacokinetics of Intraperitoneal Cefalothin and Cefazolin in Patients Being Treated for Peritoneal Dialysis-Associated Peritonitis","volume":"36","author":"DM Roberts","year":"2016","journal-title":"Perit Dial Int"},{"issue":"6","key":"pone.0312160.ref014","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/089686080302300610","article-title":"Pharmacokinetics of ceftazidime in CAPD-related peritonitis","volume":"23","author":"V Booranalertpaisarn","year":"2003","journal-title":"Perit Dial Int"},{"issue":"Suppl 1","key":"pone.0312160.ref015","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1086\/590064","article-title":"Pharmacokinetic and pharmacodynamic properties of meropenem","volume":"47","author":"DP Nicolau","year":"2008","journal-title":"Clin Infect Dis"},{"key":"pone.0312160.ref016","unstructured":"Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-sixth Informational Supplement M100-S27. CLSI, Wayne, PA, USA, 2017."},{"issue":"5","key":"pone.0312160.ref017","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3747\/pdi.2016.00023","article-title":"Intraperitoneal Meropenem for Polymicrobial Peritoneal Dialysis-Related Peritonitis","volume":"36","author":"CW De Fijter","year":"2016","journal-title":"Perit Dial Int"},{"key":"pone.0312160.ref018","unstructured":"Convention USP. USP 29, NF 24: the United States Pharmacopeia, the National Formulary. Gilbert BD, editor: United States Pharmacopeial Convention; 2005."},{"key":"pone.0312160.ref019","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/00003088-200039040-00003","article-title":"Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy","volume":"39","author":"F Thalhammer","year":"2000","journal-title":"Clinical pharmacokinetics"},{"issue":"2","key":"pone.0312160.ref020","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2174\/157488410791110779","article-title":"Intraperitoneal drug therapy: an advantage","volume":"5","author":"K Chaudhary","year":"2010","journal-title":"Current Clinical Pharmacology"},{"issue":"12","key":"pone.0312160.ref021","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.2215\/CJN.00630117","article-title":"Residual kidney function and peritoneal dialysis-associated peritonitis treatment outcomes","volume":"12","author":"R Whitty","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"pone.0312160.ref022","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/ki.1992.196","article-title":"A quantitative description of solute and fluid transport during peritoneal dialysis","volume":"41","author":"O Heimb\u00fcrger","year":"1992","journal-title":"Kidney Int"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0312160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T18:24:59Z","timestamp":1736187899000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0312160"}},"subtitle":[],"editor":[{"given":"Ankur","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0312160","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]}}}